CFO SpotlightsCareers of chief financial officers, from the filings. Records as of October 28, 2026
  1. CFO Spotlights
  2. Profiles
  3. Troy E. Wilson, Ph.D., J.D.

Profile

Troy E. Wilson, Ph.D., J.D.

Chief Financial Officer, Kura Oncology, Inc.

Former. First published here October 28, 2026; built from records as of October 28, 2026.

Kura Oncology, Inc. named Jennifer Fulk to succeed Troy E. Wilson, Ph.D., J.D., effective September 8, 2026.1

Seats

The seat in the record

CompanyTitle as filedStandingFilings
Kura Oncology, Inc. (KURA)
Pharmaceutical Preparations
Not statedFormer1

Company names link to the company's page in the record at CFO Tribune, which holds the seat history.

The record

Filing by filing, latest first

  1. September 8, 2026effective

    Kura Oncology, Inc. named Jennifer Fulk to succeed Troy E. Wilson, Ph.D., J.D., effective September 8, 2026. Profile of Jennifer Fulk.

    Wilson, Ph.D., J.D. solely with respect to such role) and principal accounting officer (replacing Thomas Doyle solely with respect to such role).

    [1] Filing by Kura Oncology, Inc., filed with the SEC on September 8, 2026. Read the filing. The record at CFO Tribune.

Sources

Sources

  1. Current report filed with the SEC, Kura Oncology, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed September 8, 2026. sec.gov; record.

Corrections and removal

If a line here is wrong, or Troy E. Wilson, Ph.D., J.D. wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.